Candles and bars need the day’s open, high and low, and
need room to be drawn in: past about a year of trading a body is thinner than a
hairline, so those three offer the longest window that fits instead.
Arcus Biosciences, Inc. reported revenue of 41M USD
for the quarter
ending 30 June 2026,
down 74.4% from 160M a year earlier.
Every figure, period by period ›
0200M400M600M800M
Q4 '21Q3 '22Q2 '23Q1 '24Q4 '24Q3 '25Q2 '26
RevenueOperating Cash FlowFree Cash FlowNet Income
How it scores
For a valuation multiple, the low end is the good end.
15 of 19 counted in the score. The rest are
measures this model does not include here, or figures these filings do not carry
— switch any of them on and the score changes.
5 of 12 counted in the score. The rest are
measures this model does not include here, or figures these filings do not carry
— switch any of them on and the score changes.
5 of 7 counted in the score. The rest are
measures this model does not include here, or figures these filings do not carry
— switch any of them on and the score changes.
11 of 13 counted in the score. The rest are
measures this model does not include here, or figures these filings do not carry
— switch any of them on and the score changes.
6 of 13 counted in the score. The rest are
measures this model does not include here, or figures these filings do not carry
— switch any of them on and the score changes.
A measure absent from a block could not be computed from this company's
filings. It is left out rather than scored as though it were bad, and the dimension is
averaged over what remains. A score is measured against a fixed scale this model states;
the bar is measured against the other companies, so the two can disagree — and where
they do, that disagreement is the more interesting figure.
Companies of a similar size
The nearest by market value among the companies read here whose shares
are quoted in USD. Size alone: nothing here says they are in the
same business.